Pacific Biosciences of Californ (PACB) Financials
PACB Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 1.7 billion | 1.0 billion |
2023-09-30 | 1.9 billion | 1.1 billion |
2023-06-30 | 1.8 billion | 1.2 billion |
2023-03-31 | 1.9 billion | 1.2 billion |
PACB Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -59.6 million | 16.6 million |
2023-09-30 | -66.0 million | 19.7 million |
2023-06-30 | -44.0 million | 17.9 million |
2023-03-31 | -98.4 million | 18.0 million |
PACB Net Income
No data available :(
PACB Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 631.7 million | - | 41.2 million |
2023-09-30 | 767.8 million | - | 43.6 million |
2023-06-30 | 829.9 million | 891.8 million | 45.8 million |
2023-03-31 | 874.9 million | 896.8 million | 48.0 million |
PACB Shares Outstanding
PACB Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 2.0 million | 44.5 million | 46.0 million | - |
2023-09-30 | 830000 | 47.5 million | 43.4 million | - |
2023-06-30 | 2.3 million | 46.2 million | 42.5 million | - |
2023-03-31 | 3.7 million | 48.9 million | 52.1 million | - |
PACB Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 58.4 million | 47.4 million |
2023-09-30 | 55.7 million | 37.8 million |
2023-06-30 | 47.6 million | 32.0 million |
2023-03-31 | 38.9 million | 29.1 million |
PACB
Price: $1.47
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.21 USD
P/E Ratio: -5.11
Exchange: NMS
Sector: Healthcare
Industry: Medical Devices
Volume: 5.8 million
Ebitda: -20.1 millionMarket Capitalization: 892.3 million